Boston Scientific Introduces Endoscopic Sleeve Gastroplasty (ESG) and Intragastric Balloon System in the Fight Against Obesity
Boston Scientific's New Offering
Boston Scientific is stepping into the expanding weight loss market with its latest innovations: the Endoscopic Sleeve Gastroplasty (ESG) and the Intragastric Balloon System (IBS). These options are geared towards patients struggling with obesity treatment.
Endoscopic Sleeve Gastroplasty (ESG)
The Endoscopic Sleeve Gastroplasty (ESG) is an incision-free weight loss procedure that significantly reduces stomach volume, making it a less invasive form of bariatric surgery for patients who may not qualify for more traditional options.
Intragastric Balloon System (IBS)
- The Intragastric Balloon System is essentially a silicone gastric balloon inserted into the stomach to temporarily occupy space and reduce its overall capacity.
- The Apollo ESG System has received authorizations from both the US FDA and CDSCO, while the Orbera365 System is indicated only for temporary use in patients with a BMI of 30-50.
According to Madan R. Krishnan, vice president and managing director, APAC Growth Markets, Boston Scientific, “With the growing incidence of obesity in India, this system provides a much-needed option for patients who may not qualify for traditional bariatric surgery but are still looking for a solution to manage their weight.”
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.